{"id":971644,"date":"2026-06-12T09:30:46","date_gmt":"2026-06-12T13:30:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/"},"modified":"2026-06-12T09:30:46","modified_gmt":"2026-06-12T13:30:46","slug":"alnylam-to-host-tenth-rnai-roundtable-webcast-series","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/","title":{"rendered":"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54552281&amp;newsitemid=20260612239247&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=0c46d07c1620c31b50f6b952bbeff9f5\">Alnylam Pharmaceuticals, Inc.<\/a> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10<sup>th<\/sup> series of \u201cRNAi Roundtable\u201d webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company\u2019s pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will be webcast live on the Investors section of the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.alnylam.com%2Fevents&amp;esheet=54552281&amp;newsitemid=20260612239247&amp;lan=en-US&amp;anchor=investors.alnylam.com%2Fevents&amp;index=2&amp;md5=ca2e6cf094e97eb73ce720ed2861e6cf\">investors.alnylam.com\/events<\/a>, and a replay will be posted on the Alnylam website approximately three hours after each event.<\/p>\n<p>\nThe 2026 RNAi Roundtable schedule is as follows:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nALN-6400: Targeting Plasminogen to Address a Wide Range of Bleeding Disorders<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nThursday, June 25, 11:00 am ET<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\nZilebesiran: Targeting Angiotensinogen to Achieve Continuous Control of Blood Pressure<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nThursday, September 17, 10:30 am ET<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\nALN-HTT02: Targeting Exon 1 of Huntingtin Gene to Reduce Progression of Huntington\u2019s Disease<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nMonday, October 26, 10:00 am ET<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\nAlnylam\u2019s leadership in RNAi therapeutics is underpinned by a broad and rapidly advancing pipeline spanning multiple therapeutic areas and stages of development. The Company is focused on its <i>Alnylam 2030<\/i> goals, including driving Growth Through Sustainable Innovation, by advancing an industry-leading pipeline of RNAi therapeutics designed to prevent, halt, or reverse disease. Specifically, the Company plans to achieve over 40 clinical programs by 2030\u2014from over 25 today\u2014and to continue expanding into new tissues, while harnessing the latest AI technologies to accelerate and optimize its discovery platform. Alnylam is investing meaningfully in R&amp;D to extend the reach of RNAi and deliver multiple new transformative medicines for patients with serious diseases and high unmet need.<\/p>\n<p><b>About Alnylam Pharmaceuticals<br \/>\n<br \/><\/b>Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its <i>Alnylam 2030<\/i> strategy to accelerate innovation and scale impact to transform human health. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54552281&amp;newsitemid=20260612239247&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=3&amp;md5=a324a7ed596dbd80bcd83c6168d83e2e\">www.alnylam.com<\/a> or follow Alnylam on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FAlnylam&amp;esheet=54552281&amp;newsitemid=20260612239247&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=17417c555953710494c5bfc61aa41f33\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Falnylam-pharmaceuticals%2F&amp;esheet=54552281&amp;newsitemid=20260612239247&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=4cafe7768843999e2cd2ec5ceba2b7ef\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FAlnylamPharma%2F&amp;esheet=54552281&amp;newsitemid=20260612239247&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=308be60c7fe7ec16c612eea68228e721\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Falnylampharma%2F&amp;esheet=54552281&amp;newsitemid=20260612239247&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=85e6a2c792bfafd3f9414f1ce4c4b32d\">Instagram<\/a>, or <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2F%40AlnylamPharmaceuticals&amp;esheet=54552281&amp;newsitemid=20260612239247&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=3e0229cbcf25fa1dc0fa2fb828469605\">YouTube<\/a>.<\/p>\n<p><b>Forward Looking Statements<br \/>\n<br \/><\/b>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam\u2019s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding Alnylam\u2019s ability to achieve the goals in its <i>Alnylam 2030 <\/i>strategy, including to drive growth through innovation; the potential to expand its pipeline to over 40 clinical programs by 2030; the potential to expand into new tissues; the potential to utilize AI technologies to accelerate and optimize its discovery platform; and the potential to deliver multiple new transformative medicines for patients should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam\u2019s ability to successfully execute on its <i>Alnylam 2030<\/i> strategy; Alnylam\u2019s ability to successfully launch, market and sell Alnylam\u2019s approved products globally, including AMVUTTRA; Alnylam\u2019s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam\u2019s product candidates; actions or advice of regulatory agencies and Alnylam\u2019s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam\u2019s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam\u2019s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam\u2019s ability to maintain strategic business collaborations; Alnylam\u2019s dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the \u201cRisk Factors\u201d filed with Alnylam\u2019s 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam\u2019s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam\u2019s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260612239247\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260612239247\/en\/<\/a><\/span><\/p>\n<p><b>Alnylam Pharmaceuticals, Inc.<br \/>\n<\/b><br \/>Christine Akinc<br \/>\n<br \/>(Investors and Media)<br \/>\n<br \/>617-682-4340<\/p>\n<p>\nJosh Brodsky<br \/>\n<br \/>(Investors)<br \/>\n<br \/>617-551-8276<\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Science Other Science Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260612239247\/en\/1161817\/3\/Alnylam_Corporate_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of \u201cRNAi Roundtable\u201d webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company\u2019s pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will be webcast live on the Investors section of the Company\u2019s website at investors.alnylam.com\/events, and a replay will be posted on the Alnylam website approximately three hours after each event. The 2026 RNAi Roundtable schedule is as follows: ALN-6400: Targeting Plasminogen to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-971644","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of \u201cRNAi Roundtable\u201d webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company\u2019s pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will be webcast live on the Investors section of the Company\u2019s website at investors.alnylam.com\/events, and a replay will be posted on the Alnylam website approximately three hours after each event. The 2026 RNAi Roundtable schedule is as follows: ALN-6400: Targeting Plasminogen to &hellip; Continue reading &quot;Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T13:30:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series\",\"datePublished\":\"2026-06-12T13:30:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/\"},\"wordCount\":882,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/\",\"name\":\"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-06-12T13:30:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/","og_locale":"en_US","og_type":"article","og_title":"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series - Market Newsdesk","og_description":"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of \u201cRNAi Roundtable\u201d webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company\u2019s pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will be webcast live on the Investors section of the Company\u2019s website at investors.alnylam.com\/events, and a replay will be posted on the Alnylam website approximately three hours after each event. The 2026 RNAi Roundtable schedule is as follows: ALN-6400: Targeting Plasminogen to &hellip; Continue reading \"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-12T13:30:46+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series","datePublished":"2026-06-12T13:30:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/"},"wordCount":882,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/","name":"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-06-12T13:30:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260612239247r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-host-tenth-rnai-roundtable-webcast-series\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alnylam to Host Tenth \u201cRNAi Roundtable\u201d Webcast Series"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/971644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=971644"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/971644\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=971644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=971644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=971644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}